Wugen
fratricide-resistant CAR-T
oncology evolved
press releases
Dec. 3, 2018
WUGEN Presents Updated Preclinical Data on Novel Allogeneic CAR-T Platform at ASH Annual Meeting
abstracts
Modeling Sézary Syndrome for Immunophenotyping and Anti-Tumor Effect of UCART and Long-Acting Interleukin-7 Combination Therapy
A Long-Acting Pharmacological Grade Interleukin-7 Molecule Logarithmically Accelerates UCART Proliferation, Differentiation, and Tumor Killing
wugen
Careers
Wugen is an Equal Opportunity Employer and does not discriminate against applicants due to race, ethnicity, gender, veteran status, or on the basis of disability or any other federal, state or local protected class.
PUBLICATIONS
An “off-the-shelf” fratricide-resistant CAR-T for the Treatment of T-cell hematologic malignancies
T-cell malignancies represent a group of hematologic cancers with high rates of relapse and mortality in patients for whom no effective targeted therapies exist. The shared expression of target antigens between chimeric antigen receptor (CAR) T-cells and malignant T-cells has limited the development.